Loading...

CGEM CULLINAN THERAPEUTICS INC US FDA Inspections 8-K Filing

CLLN

CGM

CULLINAN THERAPEUTICS INC

(CGEM)

2025 8-K

Financial Results Announced

Corporate Update

Clinical Data Update

Agreement Termination

Financial Results Report

Clinical Data Update

Corporate Update

License Agreement

Financial Statements

Financial Results

Financial Results

Clinical Trial Approval

Financial Results Announcement

Annual Meeting of Stockholders

Clinical Trial Data Announc...

Clinical Data Announcement

Appointment of CFO

Private Placement and Name ...

Financial Results Announcement

Amendment Filing

Financial Condition

Financial Results Announcement

Financial Results Announcement

Departure of Directors

Clinical Data Announcement

Financial Results Announcement

Financial Results Announcement

License Agreement and Cash ...

Equity Exchange

External Links:

Cullinan Therapeutics announced that its REZILIENT1 trial for zipalertinib in lung cancer patients met its primary endpoint, with plans for regulatory submission in the second half of 2025.

AI Assistant

CULLINAN THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.